Csm Advisors, LLC Incyte Corp Transaction History

Csm Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $606,007 - $691,605	-10,490 Reduced 6.46%	151,950 $8.78 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $44,798 - $55,499	-735 Reduced 0.45%	162,440 $10.1 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $499,335 - $611,531	7,110 Added 4.56%	163,175 $11.8 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $27,543 - $34,485	410 Added 0.26%	156,065 $12.5 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $1.41 Million - $1.76 Million	-21,300 Reduced 12.04%	155,655 $10.4 Million
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $82,725 - $103,975	1,250 Added 0.71%	176,955 $13.4 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $11.6 Million - $14 Million	175,705 New	175,705 $14 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Csm Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Csm Advisors, LLC with notifications on news.